CURE® Educated Patient® Conference Report: Summer 2022

Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.

Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.

Tecentriq plus chemotherapy lowered the risk of cancer returning or death by 50% versus chemotherapy alone in patients with stage 3 dMMR colon cancer.

In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.

In a Johns Hopkins study, 64% of African American patients with myeloma received bone-modifying drugs in their first year, compared with 77% of White patients.

ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.

Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.